Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease

Background: CVT-301, an inhaled levodopa (LD) formulation, is under development for relief of OFF periods in Parkinson's disease (PD). Previously, we reported that CVT-301 improved OFF symptoms relative to placebo. In this study, we evaluate pulmonary function in patients treated with a single...

Descripción completa

Detalles Bibliográficos
Autores principales: LeWitt, Peter A., Pahwa, Rajesh, Sedkov, Alexander, Corbin, Ann, Batycky, Richard, Murck, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994675/
https://www.ncbi.nlm.nih.gov/pubmed/29161531
http://dx.doi.org/10.1089/jamp.2016.1354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994675/
https://www.ncbi.nlm.nih.gov/pubmed/29161531
http://dx.doi.org/10.1089/jamp.2016.1354

Ejemplares similares